Replies to post #1701 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: Merrimack status

>I do not who you are refering to by "auditor" because we both know 10q' are not audited…<

Again, you fail to make a point. Quarterly reports are not formally audited by the external auditors but they are most certainly reviewed by the internal auditors. Moreover, thanks to Sarbanes-Oxley, the CEO and CFO must formally attest to the validity of the numbers.

>…but clinical data, specifically, is outside the realm of an accountant.<

This is non-responsive—nothing in my prior posts in this thread made assertions about Merrimack’s clinical data.

>What say you, GTC? Get Merrimack on the phone and give your shareholders an update!<

As a matter of policy, GTC does not—and should not—update shareholders on what is going on at Merrimack beyond what has been publicly disclosed. Imagine the effect on future partnerships if this policy were otherwise.

Finally, in case you missed it, let me repost the sentence about Merrimack from GTC’s 3Q06 press release:

“… net cash utilization of $21-25 million for 2006…includes projected fourth quarter 2006 cash receipts from our ongoing product supply commitments for Merrimack Pharmaceuticals…”

Out.